Clinical trials have been conducted almost wholly in high-income countries until recently, yet their results may not always be valid or applicable in middle- and low-income countries. A welcome recent development is the increasing number of clinical trials being conducted in the latter areas. Growth in the number of trials and their increasing costs in high-income countries are combining with globalisation to shift clinical trials to less wealthy countries (Rowland, [@r8]). Glickman *et al* ([@r2]) have shown that about a third of clinical trials conducted by the 20 largest US-based pharmaceutical companies are now conducted outside the USA, many in low-income countries.

Such globalisation of clinical trials obviously confers some benefits to the host countries, including the sharing of experiences and knowledge. It also increases the local availability of the medicines under trial, as well as familiarity with them. The trials bring revenue to the host countries while cutting costs to the pharmaceutical companies by around 10--50%. Clinical trials in India, which is emerging as a favoured global destination for research and outsourced clinical trials, was expected to have earned that country US\$1.5 billion of revenue by 2010 (Federation of Indian Chambers of Commerce and Industry, [@r1]).

As welcome as this development is, it brings in its wake challenges, provoking the debate over whether clinical trials in low-income countries are as valid as they are intended to be. Many factors come together to determine the validity of clinical trials, including the number of participants who can be recruited, the affordability and local availability of the medicines, informed consent, and ethical approval from an institutional review body or the agency accredited by the local ministry of health, among others. Ethical approval is a very important consideration, to ensure that nobody is exploited in the course of the trial and that the drug is properly shown to be safe in general application.

In the light of these considerations and challenges, two key questions arise.

-   Are clinical trials accurate and reliable in low-income countries?

-   Do the interpretations given to the results of these trials actually reflect the reality on the ground?

These issues are being raised in this paper to draw attention to the difficulties that may arise in the new global trend for clinical trials to be conducted in low-income countries. Caution is needed in the interpretation of findings from such studies.

Challenges of ethical issues, informed consent and control studies {#s1}
==================================================================

It has been suggested that the recent increase in the number of clinical trials being conducted in low- and middle-income countries is not exactly benevolent or altruistic on the part of the pharmaceutical companies. There are various other considerations (Nekkanti, [@r7]). Profit motives may underlie the clinical trials and this could affect ethical considerations.

It has been shown that as many as 15--25% of clinical studies conducted in a low-income country do not go through any institutional review board nor any ethics committee, nor have the approval of the ministry of health (Hyder *et al*, [@r3]). Even when ethical approval is given, informed consent may be an issue. High levels of illiteracy, cultural barriers, poverty and dependency could negatively influence people's comprehension and ability to give informed consent and can bring into question voluntarism and willingness. The populations of low-income countries, it has been noted (Krosin *et al*, [@r6]), are particularly vulnerable in this respect, for various reasons.

Another major issue is the standard of care. The limited resources of poor countries may lead to compromises in standards (Johnatty, [@r4]), particularly with respect to whether to use placebo in a controlled trial when there is an alternative medicine for comparison. Profit may drive a motivation for placebo to be used when this same standard may not be applied in a high-income country (Tollman *et al*, [@r10]). A strong institutional review board could ensure that no country is short-changed when it is possible to use an alternative drug. The author learned from a colleague at the University of Lagos that, for a clinical trial with the antidepressant paroxetine, in Nigeria in 1995, a drug company insisted on using a small number of patients and an open trial when the local counter-part recommended a case--control double-blind study and a much bigger sample size. The company was considering time and cost and the fact that the drug had been tested elsewhere anyway. The profit motive seemed too strong.

Kent *et al* ([@r5]) reviewed the published data from randomised clinical trials of HIV treatment, tuberculosis treatment and malaria prophylaxis in sub-Saharan Africa and concluded that there is variable adherence to established clinical guidelines of care, and researchers and ethics committees seem to take the 'local level' of care into consideration.

The case of Pfizer's clinical trials with its new drug in Kano, Nigeria, in the 1996 meningitis epidemic certainly amplifies the issues of ethical considerations and standards of care. Pfizer hastily took advantage of the epidemic to test its new drug, hoping to make a multimillion dollar profit. Several lawsuits against Pfizer resulted and there has been a large out-of-court settlement (*World Press Review*, [@r11]; Stephens, [@r9]).

Another major concern is that at the end of a trial the drug may not be affordable because the purchasing power of clients in low-income countries may be too low, especially where there is no health insurance system that can cushion them. Thus, a person who participates in a trial testing a new medication may not ultimately be able to benefit from the drug.

Conclusion {#s2}
==========

While the globalisation of clinical trials is a welcome phenomenon for the positive benefits it brings to both the host country and the pharmaceutical companies, there is a need to watch critically that the profit motive does not override the benefits. Care should be taken to interpret the resulting data, taking into consideration the challenges of informed consent. Partnership with local counter-parts while adhering to international standards should help to maintain high-quality output.
